Herantis Pharma Strengthens Management Team with New CMO
Herantis Pharma Plc
Company release 22 Jan 2021 at 9:00 am EET
Herantis Pharma Plc (“Herantis”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today announced the full-time appointment of Magnus Sjögren, MD, PhD as Chief Medical Officer. Dr. Sjögren will assume the role of Chief Medical Officer effective as of 1st of May 2021.
“We are delighted to add Magnus Sjögren to our management team. He brings an impressive skill set strongly complementary to our focus therapeutic areas at Herantis and a distinguished CV, making him our top choice for CMO. Dr. Sjögren joins at a key time for the company as we continue to advance and accelerate our neurological and lymphatic programs,” said Craig Cook, CEO of Herantis Pharma. “This is such an exciting time for the company and his very successful track record in clinical research and translational medicine in neuroscience and other diseases will be a real asset for Herantis Pharma.”
Dr Sjogren is a neuroscience expert with a focus on neurodegenerative diseases, and in addition has experience in other areas relevant to Herantis’ programs including oncology and inflammation. He has held several senior executive and scientific positions at major pharmaceutical and biotechnology companies, including Chief Medical Officer at DiaGenic, Vice President Global Exploratory Development at UCB Pharma, Global Head of Translational Medicine in Schering-Plough and Senior Clinical Research Director at AstraZeneca. He is highly knowledgeable on Herantis’ compounds, having consulted to the company for several years in our key programs. He is an Associate Professor at Gothenburg University, a Research Lecturer at Copenhagen University, a trained psychiatrist, and the author of more than 135 scientific publications. He received his Doctor of Medicine from Linköping University in Sweden, his PhD in clinical psychiatry, and his postdoc in clinical neuroscience from the University of Gothenburg, Sweden.
“Herantis represents truly novel clinical stage research in disease modifying therapies, using novel biological and gene therapy approaches. I am thrilled to be given the opportunity to oversee the clinical development of Herantis’ compelling pipeline programs in neurodegenerative and lymphatic diseases and very much look forward to working with the whole Herantis team as we advance our portfolio to provide innovative treatments that can make a real difference for patients,” commented Dr. Sjögren, CMO of Herantis Pharma.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases and break the boundaries of standard therapeutic approaches. Leveraging deep scientific brilliance in protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis is advancing a rich pipeline of regenerative biological and gene therapies for high impact diseases. These include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, and ii. Lymfactin® VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that slow, stop, or even reverse the course of diseases, and bring much needed innovation to these underserved diseases. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.